×
About 78,186 results

ALLMedicine™ Non-small Cell Lung Cancer Center

Research & Reviews  37,659 results

Dramatic Response to Pembrolizumab Monotherapy in a Patient With ARID1A-Mutant Lung Ade...
https://doi.org/10.1016/j.cllc.2021.01.011
Clinical Lung Cancer; Harada G, Amano MT et. al.

Mar 4th, 2021 - Immunotherapy based on immune checkpoint inhibitors (ICIs) either alone or in combination with platinum-based chemotherapy has dramatically changed the therapeutic scenario in non-small cell lung cancer. However, only a subset of patients derives ...

A burned-out CD8+ T-cell subset expands in the tumor microenvironment and curbs cancer ...
https://doi.org/10.1158/2159-8290.CD-20-0962
Cancer Discovery; Sanmamed MF, Nie X et. al.

Mar 4th, 2021 - Specific mechanisms by which tumor infiltrating lymphocytes (TIL) become dysfunctional remain poorly understood. Here, we employed a two-pronged approach using single-cell mass cytometry and tissue imaging technologies to dissect TILs from 25 rese...

SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-...
https://doi.org/10.1136/jitc-2020-001496
Journal for Immunotherapy of Cancer; Redin E, Garmendia I et. al.

Mar 4th, 2021 - The use of immune-checkpoint inhibitors has drastically improved the management of patients with non-small cell lung cancer (NSCLC), but innate and acquired resistances are hurdles needed to be solved. Immunomodulatory drugs that can reinvigorate ...

Identified lung adenocarcinoma metabolic phenotypes and their association with tumor im...
https://doi.org/10.1007/s00262-021-02896-6 10.1016/j.ccm.2019.10.001 10.1056/NEJMoa1507643 10.7150/thno.21524 10.1016/j.cell.2015.08.016 10.1016/j.cell.2015.08.012 10.1016/j.pharmthera.2018.11.004 10.1038/s41571-019-0203-7 10.4110/in.2020.20.e10 10.2147/ITT.S125070 10.1097/JTO.0b013e318174e9a7 10.1016/j.thorsurg.2020.01.009 10.1016/j.tranon.2019.12.010 10.1016/j.jtho.2017.03.010 10.1038/nature10350 10.1002/bs.3830120210 10.1023/A:1023949509487 10.1186/1471-2105-14-7 10.1016/j.celrep.2016.12.019 10.1093/nar/gkv007 10.1089/omi.2011.0118 10.1073/pnas.0506580102 10.5812/ijem.3505 10.1038/s41591-018-0136-1 10.1172/JCI91190 10.1186/1471-2105-12-77 10.1093/bioinformatics/btw313 10.1126/science.1203486 10.1093/bib/bbaa026 10.1126/science.aaf8399 10.1200/EDBK_237987 10.1038/s41568-019-0116-x 10.1080/21645515.2017.1303582 10.1038/s41568-018-0081-9 10.4049/jimmunol.178.9.5552 10.1172/JCI45817 10.1186/s40164-020-00165-3 10.1038/s41573-018-0007-y 10.1111/febs.15028 10.1016/j.cmet.2018.02.024 10.1038/s41585-019-0263-6 10.1007/978-3-319-67577-0_9 10.1016/j.cell.2019.08.012 10.2147/CMAR.S173941 10.1002/cam4.3240
Cancer Immunology, Immunotherapy : CII; Wu XN, Su D et. al.

Mar 4th, 2021 - Lung adenocarcinoma (LUAD), a subtype of non-small cell lung cancer (NSCLC), causes high mortality around the world. Previous studies have suggested that the metabolic pattern of tumor is associated with tumor response to immunotherapy and patient...

see more →

Guidelines  151 results

Multi-center observational study on the adherence, quality of life, and adverse events in lung cancer patients treated with tyrosine kinase inhibitors
https://pubmed.ncbi.nlm.nih.gov/32746691/
Journal of Oncology Pharmacy Practice; Rosentreter J

Aug 2nd, 2020 - Cancer patients tend to prefer oral instead of parenteral chemotherapy. To date, there is little evidence on the medication adherence in cancer patients. We investigated medication adherence to tyrosine kinase inhibitors in patients suffering from...

Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous non-small cell lung cancer: a randomized, double-blind, phase 3...
https://www.jto.org/article/S1556-0864(20)30595-5/pdf
Journal of Thoracic Oncology; Yang Y

Jul 24th, 2020 - Sintilimab, an anti-programmed death 1 antibody, plus pemetrexed and platinum had shown promising efficacy for nonsquamous non-small cell lung cancer in a phase 1b study. We conducted a randomized, double-blind, phase 3 study to compare the ef...

Adjuvant osimertinib extends DFS in EGFR-mutated NSCLC
https://www.healio.com/hematology-oncology/lung-cancer/news/online/{641f2259-d903-472a-acbb-681a7bbd3eec}/adjuvant-osimertinib-extends-dfs-in-egfr--mutated-nsclc

May 28th, 2020 - Adjuvant osimertinib significantly prolonged DFS for patients with EGFR-mutated non-small cell lung cancer, according to results of the randomized phase 3 ADAURA trial scheduled for presentation during the ASCO20 Virtual Scientific Program.

Durable Responses Elicited with Nivolumab Plus Ipilimumab in Advanced NSCLC
https://www.targetedonc.com/view/durable-responses-elicited-with-nivolumab-plus-ipilimumab-in-advanced-nsclc

May 28th, 2020 - Frontline treatment with the combination of with nivolumab (Opdivo) plus ipilimumab (Yervoy) induced durable and long-term efficacy benefits in patients with advanced non-small cell lung cancer (NSCLC) and tumor PD-L1 expression of at least 1% or ...

OS Benefit Observed With Frontline Nivolumab/Ipilimumab Plus Limited Chemotherapy in NSCLC
https://www.targetedonc.com/view/os-benefit-observed-with-frontline-nivolumab-ipilimumab-plus-limited-chemotherapy-in-nsclc

May 28th, 2020 - The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) when administered in the frontline setting for patients with metastatic or recurrent non-small cell lung cancer (NSCLC) along with 2 cycles of platinum-doublet chemotherapy, should be c...

see more →

Drugs  253 results see all →

Clinicaltrials.gov  38,943 results

Dramatic Response to Pembrolizumab Monotherapy in a Patient With ARID1A-Mutant Lung Ade...
https://doi.org/10.1016/j.cllc.2021.01.011
Clinical Lung Cancer; Harada G, Amano MT et. al.

Mar 4th, 2021 - Immunotherapy based on immune checkpoint inhibitors (ICIs) either alone or in combination with platinum-based chemotherapy has dramatically changed the therapeutic scenario in non-small cell lung cancer. However, only a subset of patients derives ...

A burned-out CD8+ T-cell subset expands in the tumor microenvironment and curbs cancer ...
https://doi.org/10.1158/2159-8290.CD-20-0962
Cancer Discovery; Sanmamed MF, Nie X et. al.

Mar 4th, 2021 - Specific mechanisms by which tumor infiltrating lymphocytes (TIL) become dysfunctional remain poorly understood. Here, we employed a two-pronged approach using single-cell mass cytometry and tissue imaging technologies to dissect TILs from 25 rese...

SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-...
https://doi.org/10.1136/jitc-2020-001496
Journal for Immunotherapy of Cancer; Redin E, Garmendia I et. al.

Mar 4th, 2021 - The use of immune-checkpoint inhibitors has drastically improved the management of patients with non-small cell lung cancer (NSCLC), but innate and acquired resistances are hurdles needed to be solved. Immunomodulatory drugs that can reinvigorate ...

Identified lung adenocarcinoma metabolic phenotypes and their association with tumor im...
https://doi.org/10.1007/s00262-021-02896-6 10.1016/j.ccm.2019.10.001 10.1056/NEJMoa1507643 10.7150/thno.21524 10.1016/j.cell.2015.08.016 10.1016/j.cell.2015.08.012 10.1016/j.pharmthera.2018.11.004 10.1038/s41571-019-0203-7 10.4110/in.2020.20.e10 10.2147/ITT.S125070 10.1097/JTO.0b013e318174e9a7 10.1016/j.thorsurg.2020.01.009 10.1016/j.tranon.2019.12.010 10.1016/j.jtho.2017.03.010 10.1038/nature10350 10.1002/bs.3830120210 10.1023/A:1023949509487 10.1186/1471-2105-14-7 10.1016/j.celrep.2016.12.019 10.1093/nar/gkv007 10.1089/omi.2011.0118 10.1073/pnas.0506580102 10.5812/ijem.3505 10.1038/s41591-018-0136-1 10.1172/JCI91190 10.1186/1471-2105-12-77 10.1093/bioinformatics/btw313 10.1126/science.1203486 10.1093/bib/bbaa026 10.1126/science.aaf8399 10.1200/EDBK_237987 10.1038/s41568-019-0116-x 10.1080/21645515.2017.1303582 10.1038/s41568-018-0081-9 10.4049/jimmunol.178.9.5552 10.1172/JCI45817 10.1186/s40164-020-00165-3 10.1038/s41573-018-0007-y 10.1111/febs.15028 10.1016/j.cmet.2018.02.024 10.1038/s41585-019-0263-6 10.1007/978-3-319-67577-0_9 10.1016/j.cell.2019.08.012 10.2147/CMAR.S173941 10.1002/cam4.3240
Cancer Immunology, Immunotherapy : CII; Wu XN, Su D et. al.

Mar 4th, 2021 - Lung adenocarcinoma (LUAD), a subtype of non-small cell lung cancer (NSCLC), causes high mortality around the world. Previous studies have suggested that the metabolic pattern of tumor is associated with tumor response to immunotherapy and patient...

see more →

News  1,173 results

Combo Immunotherapy in NSCLC: Not These Two Drugs
https://www.medscape.com/viewarticle/945603

Feb 9th, 2021 - Dual immunotherapy with pembrolizumab (Keytruda) and ipilimumab (Yervoy) did not improve survival outcomes over pembrolizumab alone in the treatment of metastatic non-small cell lung cancer (NSCLC) in the KEYNOTE-598 trial. However, the combinatio...

Neoadjuvant Atezolizumab Safe in Resectable Lung Cancer
https://www.medscape.com/viewarticle/945607

Feb 9th, 2021 - Neoadjuvant atezolizumab prior to lung cancer surgery was well tolerated by patients with stage IB-IIIB lung cancer and produced a 21% major pathologic response rate, according to the primary analysis of the Lung Cancer Mutation Consortium (LCMC) ...

US Cancer Death Rates Drop for Second Year in a Row
https://www.medscape.com/viewarticle/944030

Jan 12th, 2021 - For the second year in a row, mortality from cancer has fallen in the United States, driven largely by reductions in the incidence of, and death from, non-small cell lung cancer (NSCLC) in men and women, according to a new report from the American...

FDA OKs Osimertinib (Tagrisso) as First Adjuvant Drug for NSCLC
https://www.medscape.com/viewarticle/942997

Dec 20th, 2020 - The US Food and Drug Administration (FDA) has approved osimertinib (Tagrisso, AstraZeneca) as the first adjuvant treatment for adults with early-stage non-small cell lung cancer (NSCLC) bearing epidermal growth factor receptor-mutated (EGFR) exon ...

Sequencing Therapeutic Options for ALK+ NSCLC: Standards of Care and Alternatives
https://decisionpoint.medscape.com/oncology/viewarticle/941617

Dec 15th, 2020 - Key Takeaways: The next-generation tyrosine kinase inhibitor (TKI) drugs such as alectinib, brigatinib, and lorlatinib have a potential benefit over crizotinib in terms of maximizing survival for patients with ALK-rearranged non-small cell lung ca...

see more →

Patient Education  7 results see all →